ArticleClinical pharmacology and therapeutics2022

Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.

Eunjin Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.